Abstract
Non-small cell lung cancer (NSCLC) consists of several subtypes, including adenocarcinoma, squamous cell lung cancer, large cell lung cancer, and other rarer types. Platinum-based regimens are currently the standard for treatment of advanced NSCLC. Nedaplatin is reportedly associated with a high response rate in squamous cell lung cancer. However, the relevant studies are small and mainly descriptive. The purpose of this meta-analysis was therefore to compare the efficacy of nedaplatin in squamous cell lung cancer with that in non-squamous cell lung cancer. Studies concerning nedaplatin-based regimens in NSCLC patients were retrieved from PubMed and EMBASE. The response rate for nedaplatin-based regimens in squamous cell lung cancer (ORR: 55.6%, 95% CI: 52.5-58.7%) was higher (OR: 1.55, 95% CI: 1.17-2.05) than that for non-squamous cell lung cancer (ORR: 34.4%, 95% CI: 32.3-36.5%). In addition, Taxane plus nedaplatin produced a longer overall and progress-free survival than CPT-11 or gemcitabine plus nedaplatin. To verify these findings, future well-controlled clinical studies will be needed.
Highlights
Most of non-small cell lung cancer (NSCLC) patients are diagnosed at an advanced stage and have lost their chance for surgery
The antitumor activity of nedaplatin may be mediated by mechanisms different from p53-dependent early apoptosis [25]
According to a phase II study, nedaplatin is more active against squamous cell lung cancer than lung adenocarcinoma [7]
Summary
Most of non-small cell lung cancer (NSCLC) patients are diagnosed at an advanced stage and have lost their chance for surgery. In a study of 1139 patients, platinum-based regimens all had similar efficacies, with a response rate of nearly 19% and a median overall survival time of 7.9 months [3]. Subsequent research demonstrated that nedaplatin-based regimens have favorable efficacy in squamous cell histology. Attention has been paid to the efficacy of nedaplatin and its comparison to cisplatin, few studies have focused on its histological specificity. This systemic review was designed to quantitatively compare the efficacy of a nedaplatin-based regimen between squamous cell lung cancer and non-squamous cell lung cancer
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
